# A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Tiral in Healthy Male Volunteers

> **NCT06736587** · PHASE1 · RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 76 (estimated)

## Conditions studied

- Autoimmune Diseases

## Interventions

- **DRUG:** DWP212525 10mg
- **DRUG:** DWP212525 30mg
- **DRUG:** DWP212525 50mg
- **DRUG:** DWP212525 100mg
- **DRUG:** DWP212525 200mg
- **DRUG:** DWP212525 400mg
- **DRUG:** DWP212525 placebo

## Key facts

- **NCT ID:** NCT06736587
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-10
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06736587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06736587, "A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Tiral in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06736587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*